Aminoglycosides provide effective bactericidal activity against:
· gram-negative bacilli
· some aerobic gram-positive bacteria
· some protozoa.
Aminoglycosides currently in use include:
· amikacin sulfate
· gentamicin sulfate
· kanamycin sulfate
· neomycin sulfate
· paromomycin sulfate
· streptomycin sulfate
· tobramycin sulfate.
Because aminoglycosides are absorbed poorly from the GI tract, they’re usually given parenterally. After I.V. or I.M. administration, aminoglycoside absorption is rapid and complete.
Aminoglycosides are distributed widely in extracellular fluid. They readily cross the placental barrier, but don’t cross the blood-brain barrier.
Aminoglycosides aren’t metabolized. They’re excreted primarily unchanged by the kidneys.
Aminoglycosides act as bactericidal drugs (remember, this means they kill bacteria) against susceptible organisms by binding to the bacterium’s 30S subunit, a specific ribosome in the microorgan-ism, thereby interrupting protein synthesis and causing the bac-terium to die.
Bacterial resistance to aminoglycosides may be related to:
§ failure of the drug to cross the cell membrane
§ altered binding to ribosomes
§ destruction of the drug by bacterial enzymes.
Some gram-positive enterococci resist aminoglycoside transport across the cell membrane. When penicillin is used with aminogly-coside therapy, the cell wall is altered, allowing the aminoglyco-side to penetrate the bacterial cell.
Aminoglycosides are most useful in treating:
§ infections caused by gram-negative bacilli
§ serious nosocomial (hospital-acquired) infections, such as gram-negative bacteremia (abnormal presence of microorganisms in the bloodstream), peritonitis (inflammation of the peritoneum, the membrane that lines the abdominal cavity), and pneumonia, in critically ill patients
§ urinary tract infections (UTIs) caused by enteric bacilli that are resistant to less toxic antibiotics, such as penicillins and cephalosporins
§ infections of the central nervous system (CNS) and the eye (treated with local instillation).
Aminoglycosides are used in combination with penicillins to treat gram-positive organisms, such as staphylococcal or enterococcal infections. Combination therapy increases the drugs’ effective-ness.
Aminoglycosides are inactive against anaerobic bacteria.
Individual aminoglycosides may have their own particular useful-ness:
§ Streptomycin is active against many strains of mycobacteria, in-cluding Mycobacterium tuberculosis, and against the gram-posi-tive bacteria Nocardia and Erysipelothrix.
§ Amikacin, gentamicin, and tobramycin are active against Acine-tobacter, Citrobacter, Enterobacter, Klebsiella, Proteus (indole-positive and indole-negative), Providencia, Serratia, Escherichiacoli, and Pseudomonas aeruginosa.
Carbenicillin and ticarcillin reduce the effects of amikacin, gen-tamicin, kanamycin, neomycin, streptomycin, and tobramycin. This is especially true if the penicillin and aminoglycoside are mixed in the same container or I.V. line.
Amikacin, gentamicin, kanamycin, neomycin, streptomycin, and tobramycin administered with neuromuscular blockers increase neuromuscular blockade, resulting in increased muscle relaxation and respiratory distress.
Toxicity to the kidneys may result in renal failure; toxicity to the neurologic system results in peripheral neuropathy with numb-ness and tingling of the extremities. The risk of renal toxicity also increases when amikacin, gentamicin, kanamycin, or tobramycin is taken with cyclosporine, amphotericin B, or acyclovir.
The symptoms of ototoxicity (damage to the ear) caused by aminoglycosides may be masked by antiemetic drugs. Loop diuret-ics taken with aminoglycosides increase the risk of ototoxicity. Hearing loss may occur in varying degrees and may be irre-versible. (See Adverse reactions to aminoglycosides.)